Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Adlai Nortye Ltd. American Depositary Shares (ANL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
03/25/2025: ANL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -36.31% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 03/25/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 114.76M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 6639 | Beta - | 52 Weeks Range 1.85 - 17.48 | Updated Date 02/26/2025 |
52 Weeks Range 1.85 - 17.48 | Updated Date 02/26/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.18 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -1293.38% |
Management Effectiveness
Return on Assets (TTM) -46.41% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -14648427 | Price to Sales(TTM) 15.79 |
Enterprise Value -14648427 | Price to Sales(TTM) 15.79 | ||
Enterprise Value to Revenue 3.81 | Enterprise Value to EBITDA - | Shares Outstanding 31236900 | Shares Floating 52398012 |
Shares Outstanding 31236900 | Shares Floating 52398012 | ||
Percent Insiders 6.96 | Percent Institutions 0.19 |
Analyst Ratings
Rating 4 | Target Price 9 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Adlai Nortye Ltd. American Depositary Shares
Company Overview
History and Background
Adlai Nortye Ltd. is a biopharmaceutical company focused on developing innovative oncology medicines. Founded in 2004, it has focused on novel therapies for cancer treatment.
Core Business Areas
- Drug Development: Research, development, and commercialization of novel oncology drugs.
- Clinical Trials: Conducting clinical trials to assess the safety and efficacy of their drug candidates.
- Partnerships: Collaborating with other pharmaceutical companies and research institutions.
Leadership and Structure
The leadership team consists of experienced executives in drug development and commercialization. The organizational structure typically includes research, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- AN2025 (buparlisib): A pan-PI3K inhibitor targeting the PI3K pathway in cancer. Market share is dependent on regulatory approvals and commercial success. The competitors include pharmaceutical companies targeting the PI3K pathway.
- AN0025 (Afuresertib): An AKT inhibitor targeting the AKT pathway in cancer. Market share is also dependent on approval and sales. Competitors include those with other AKT inhibitors in development or on the market.
Market Dynamics
Industry Overview
The oncology drug market is a large and growing market driven by an aging population and increasing cancer incidence. It is highly competitive with numerous pharmaceutical companies developing and marketing cancer therapies.
Positioning
Adlai Nortye aims to establish itself as a leader in developing novel oncology therapies, particularly in areas of unmet need. Competitive advantage is through its proprietary drug candidates and technology platform.
Total Addressable Market (TAM)
The global oncology market is estimated to be worth hundreds of billions of dollars. Adlai Nortye's position within this TAM depends on the commercial success of its drugs.
Upturn SWOT Analysis
Strengths
- Novel drug candidates in the pipeline
- Experienced management team
- Strategic partnerships
Weaknesses
- Limited commercial infrastructure
- Dependence on clinical trial success
- Competition from larger pharmaceutical companies
Opportunities
- Expanding into new markets
- Securing regulatory approvals for drug candidates
- Further partnerships and collaborations
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
Competitors and Market Share
Key Competitors
- MRK
- PFE
- BMY
- NVS
- AZN
Competitive Landscape
Adlai Nortye faces competition from established pharmaceutical companies with greater resources and established market presence. It needs to continue to innovate and secure regulatory approvals to compete effectively.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is tied to clinical trial progress, regulatory approvals, and commercialization efforts.
Future Projections: Future projections depend on analyst estimates and the success of its drug candidates.
Recent Initiatives: Recent initiatives include advancing clinical trials for its lead drug candidates and seeking regulatory approvals.
Summary
Adlai Nortye is a biopharmaceutical company focused on developing oncology medicines. The company's success hinges on clinical trial outcomes and regulatory approvals for its drug candidates. While it possesses innovative drugs and an experienced team, it faces challenges from established competitors with greater resources and requires funds to operate. The company's growth trajectory depends on successfully navigating the regulatory landscape and securing strategic partnerships.
Similar Companies
AZN
AstraZeneca PLC ADR
AZN
AstraZeneca PLC ADR
BMY
Bristol-Myers Squibb Company
BMY
Bristol-Myers Squibb Company
MRK
Merck & Company Inc
MRK
Merck & Company Inc
NVS
Novartis AG ADR
NVS
Novartis AG ADR
PFE
Pfizer Inc
PFE
Pfizer Inc
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adlai Nortye Ltd. American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-09-29 | CEO & Chairman Mr. Yang Lu | ||
Sector Healthcare | Industry Biotechnology | Full time employees 127 | Website https://www.adlainortye.com |
Full time employees 127 | Website https://www.adlainortye.com | ||
Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.